ECE2022 Eposter Presentations Pituitary and Neuroendocrinology (211 abstracts)
‘The efficiency of the treatment by Sandostatin-Lar in patients with non-functional pituitary macroadenomas’
Malika Mirtukhtaeva 1 , Ashley Grossman 2 , Nitin Leekha 3 , Alisher Akbutaev 4 & Urmanova Yulduz 5
1Republican Specialized Scientific Practical Medical Center of Endocrinology of Public Health Ministry named by acad. Ya.Kh. Turakulov, Tashkent, Uzbekistan; 2University of Oxford Senior Research Fellow, Green Templeton College, United Kingdom; 3Jaypee Hospital, Sector 128, Noida, India, Oncology Department, Noida, India; 4Republican Specialized Scientific Practical Medical Center of Endocrinology of Public Health Ministry named by acad. Ya.Kh. Turakulov, Department of Neurosurgery, Tashkent, Uzbekistan; 5Tashkent Pediatric Medical Institute, Department of Endocrinology, Tashkent, Uzbekistan
The purpose of the study: Is to study the efficiency of the treatment by Sandostatin-Lar in patients with non-functional pituitary macroadenomas (NFPA)
Material and methods.: Under our observation there were 20 patients with NFPA, of whom women were 8, men - 12. The average age of patients was 29,2/36.4 years. All patients were subjected to transnasal adenomectomy of pituitary gland (TAG) in our clinic. The whole patients were performed by research complex, which included Chemilyuminiscent hormonal (STH, IGF-1, Prolactin, LH, FSH, TSG, ACTH, Cortizol, etc.), ophthalmological (Eye bottom, field of view) and X-ray studies (CT, MRI of the Turkish saddle).
Results: According to our data, In all 20 patients, the average sizes of the pituitary tumor before TAG were in range 3.1 x 3.4 x 3.0 cm. Patients were divided into 2 groups: patients of 1 st group received after TAG the treatment by Sandostatin-Lar during 3 months, patients of 2 nd group not received Sandostatin-Lar\. The Sandostatin-Lar was prescribed 20 mg every 4 weeks for 3 months. The preliminary results showed the stabilization of the tumor residue in 7 of 10 patients (70%) in the group of combined treatment compared to 10 patients from 2 nd group who did not received Sandostatin-Lar.
Conclusions: It is necessary further continuation of research, taking into account immunocytochemical studies and biomarkers.
Article tools
My recent searches
My recently viewed abstracts
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more